NOVEL MTOR INHIBITOR COMPOUNDS
Novel compounds having formula (I) and methods of using these compounds to treat diseases, conditions, and disorders are described.
1 . A compound of formula (I), a pharmaceutically acceptable salt thereof, or an enantiomer thereof,
wherein:
R 1 , R 2 and R 3 are each independently selected from hydrogen or OH.
2 . The compound as claimed in claim 1 , having formula (II)
a pharmaceutically acceptable salt thereof, or an enantiomer thereof.
3 . The compound as claimed in claim 1 , having formula (III)
a pharmaceutically acceptable salt thereof, or an enantiomer thereof.
4 . The compound as claimed in claim 1 , having the formula (IV):
a pharmaceutically acceptable salt thereof, or an enantiomer thereof.
5 . The compound as claimed in claim 1 , wherein when R 1 is OH, R 2 and R 3 are each independently H.
6 . The compound as claimed in claim 1 , wherein when R 2 is OH, R 1 and R 3 are each independently H.
7 . The compound as claimed in claim 1 , wherein when R 3 is OH, R 1 and R 2 are each independently H.
8 . A composition comprising the compound as claimed in claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
9 . The composition according to claim 8 , comprising between 0.001% and 5% of the compound by weight relative to the total weight of the composition.
10 . The composition according to claim 8 , in a form suitable for oral or topical administration.
11 . The composition according to claim 10 , in a form suitable for topical administration.
12 . A method for treating diseases involving an mTOR enzyme with serine-threonine kinase activity, comprising administering to a subject in need thereof a composition according to claim 8 .
13 . The method according to claim 12 , for the treatment of dermatological complaints associated with a keratinization disorder with a proliferative, inflammatory and/or immunoallergic component.
14 . The method according to claim 13 , wherein the dermatological complaint is selected from psoriasis, atopic dermatitis, actinic keratosis or acne.
15 . The method according to claim 12 , for the treatment of atopic dermatitis.
16 . The method according to claim 15 , for the treatment of the inflammatory component of atopic dermatitis.
17 . The method according to claim 15 , for reinforcing the barrier function in a patient suffering from atopic dermatitis.
18 . A method of treating a disease, disorder, or condition involving mTOR production, wherein the method comprises administering to a subject, the pharmaceutical composition as claimed in claim 8 to inhibit the production of mTOR in the subject.